Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine.
Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine.
复制标题
乳腺癌患者化疗期间甲状腺功能下降的意义：三碘甲状腺原氨酸的化疗增敏作用。
DOI：
10.1186/1471-2407-13-334
复制
发表时间：
2013-07-06
期刊：
影响因子：
3.8
通讯作者：
Kong L
中科院分区：
文献类型：
--
作者：
Huang J;Jin L;Ji G;Xing L;Xu C;Xiong X;Li H;Wu K;Ren G;Kong L
甲状腺激素已被证明可以调节乳腺癌细胞的生长，细胞中甲状腺激素的缺乏或减少可能会引起G 0-G1期的增殖停滞或线粒体活性减弱，这使得细胞通过转化为低代谢状态而对癌症治疗不敏感。这种生物学现象可能有助于解释为什么甲状腺功能减退、甲状腺功能亢进和功能正常的乳腺癌患者的治疗效果和预后各不相同。然而，乳腺癌患者甲状腺功能异常一直被认为主要是由甲状腺疾病引起的，化疗对甲状腺功能的影响研究较少，化疗期间甲状腺功能的改变是否会影响化疗的疗效尚不清楚。因此，本研究旨在了解乳腺癌患者化疗期间甲状腺功能和非甲状腺疾病综合征（NTIS）的变化，探讨甲状腺激素对化疗疗效的影响。本文分析了685例乳腺疾病患者（乳腺癌369例，乳腺良性病变316例）在初诊和化疗期间的甲状腺激素和NTIS患病率。采用化疗增敏试验评价甲状腺激素对化疗效果的影响，比较化疗药物联合三碘甲腺原氨酸（T3）与单纯化疗药物对乳腺癌细胞的化疗效果。在乳腺癌中，初次诊断时的NTIS患病率较高，化疗期间也有所增加，但在下一个化疗疗程前下降。化疗期间甲状腺激素明显下降。T3能增强MCF-7对5-Fu和紫杉醇的化疗敏感性，使MCF-7细胞由G 0-G1期进入S期。在MDA-MB-231中发现了类似的T3化学增敏作用。比较不同T3使用方式组间的化疗效果，发现小剂量T3预处理、大剂量T3联合5-Fu或在化疗过程中使用5-Fu均可达到化疗增敏作用，但小剂量T3预处理至化疗结束可能是一种更安全有效的治疗方法。因此，在乳腺癌患者化疗过程中，甲状腺激素水平下降是普遍存在的。另一方面，甲状腺激素可通过抑制增殖活跃期的肿瘤细胞而增强化疗疗效，这可能为乳腺癌尤其是化疗期间甲状腺功能减退的患者提供一种新的辅助治疗方法。
Thyroid hormones have been shown to regulate breast cancer cells growth, the absence or reduction of thyroid hormones in cells could provoke a proliferation arrest in G0-G1 or weak mitochondrial activity, which makes cells insensitive to therapies for cancers through transforming into low metabolism status. This biological phenomenon may help explain why treatment efficacy and prognosis vary among breast cancer patients having hypothyroid, hyperthyroid and normal function. Nevertheless, the abnormal thyroid function in breast cancer patients has been considered being mainly caused by thyroid diseases, few studied influence of chemotherapy on thyroid function and whether its alteration during chemotherapy can influence the respose to chemotherapy is still unclear. So, we aimed to find the alterations of thyroid function and non-thyroidal illness syndrome (NTIS) prevalence druing chemotherapy in breast cancer patients, and investigate the influence of thyroid hormones on chemotherapeutic efficacy. Thyroid hormones and NTIS prevalence at initial diagnosis and during chemotherapy were analyzed in 685 breast diseases patients (369 breast cancer, 316 breast benign lesions). The influence of thyroid hormones on chemotherapeutic efficacy was evaluated by chemosensitization test, to compare chemotherapeutic efficacy between breast cancer cells with chemotherapeutics plus triiodothyronine (T3) and chemotherapeutics only. In breast cancer, NTIS prevalence at the initial diagnosis was higher and increased during chemotherapy, but declined before the next chemotherapeutic course. Thyroid hormones decreased signigicantly during chemotherapy. T3 can enhance the chemosensitivity of MCF-7 to 5-Fu and taxol, with progression from G0-G1 phase to S phase. The similar chemosensitization role of T3 were found in MDA-MB-231. We compared chemotherapeutic efficacy among groups with different usage modes of T3, finding pretreatment with lower dose of T3, using higher dose of T3 together with 5-Fu or during chemotherapy with 5-Fu were all available to achieve chemosensitization, but pretreatment with lower dose of T3 until the end of chemotherapy may be a safer and more efficient therapy. Taken together, thyroid hormones decreasing during chemotherapy was found in lots of breast cancer patients. On the other hand, thyroid hormones can enhance the chemotherapeutic efficacy through gatherring tumor cells in actively proliferating stage, which may provide a new adjuvant therapy for breast cancer in furture, especially for those have hypothyroidism during chemotherapy.
登录
查看更多内容
影响因子：
5.1
作者：
OGILVYSTUART, AL;SHALET, SM;GATTAMANENI, HR
通讯作者：
GATTAMANENI, HR
影响因子：
3.8
作者：
Kumar, N;Allen, KA;Jacobsen, PB
通讯作者：
Jacobsen, PB
影响因子：
6.2
作者：
Cristofanilli, M;Yamamura, Y;Hortobagyi, GN
通讯作者：
Hortobagyi, GN
影响因子：
8
作者：
Dinda, S;Sanchez, A;Moudgil, V
通讯作者：
Moudgil, V
影响因子：
3.2
作者：
JONCKHEER, MH;BLOCKX, P;BECKERS, C
通讯作者：
BECKERS, C